The Renal Drug Handbook: The Ultimate Prescribing Guide for Renal Practitioners, 5th Edition

Product Information

Hasan M, Sutradhar I, Gupta RD, Sarker M. Prevalence of chronic kidney disease in South Asia: a systematic review. BMC Nephrol. 2018;19(1):1–12. Purpose: This is the ultimate prescribing guide for nephrologists or physicians who encounter patients with renal impairment. It provides concise drug information and describes how to appropriately prescribe and administer the medications in this patient population. Alahdal AM, Elberry AA. Evaluation of applying drug dose adjustment by physicians in patients with renal impairment. Saudi Pharm J. 2012;20(3):217–20.

Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, et al. Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease. JACC: Heart Fail. 2019;7(1):25–32. Initiative KDOQ. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:1–S290.Tesfaye WH, Castelino RL, Wimmer BC, Zaidi STR. Inappropriate prescribing in chronic kidney disease: a systematic review of prevalence, associated clinical outcomes and impact of interventions. Int J Clin Pract. 2017;71(7):e12960.

Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta‐analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32(4):147–58.

Summary

Abdullah A, Ahmad N, Atif M, Khan S, Wahid A, Ahmad I et al. Treatment Outcomes of Childhood Tuberculosis in Three Districts of Balochistan, Pakistan: Findings from a Retrospective Cohort Study.J Trop Pediatr. 2020. Blood Results in Clinical Practice: A Practical Guide to Interpreting Blood Test Results - 2nd ed. (2019) Neerkin J, Brennan M, Jamal H. Use of opioids in patients with impaired renal function. In.: Nottingham, Engl: Palliativedrugs. com;2012. Gulalai, Ahmad N, Wahid A, Khan A, Atif M, Khan A. Evaluation of management and factors associated with hypertension control in hemodialysis patients at a tertiary-care hospital in Pakistan. Drugs Ther Perspect. 2020;36(9):396–403.